ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1128

Implications of ADPKD Diagnosis at Young Age: A Post Hoc Analysis of the TEMPO 3:4 Trial

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Janssens, Peter, KULeuven, Leuven, Belgium
  • De Rechter, Stephanie Le, University Hospitals Leuven, Leuven, Belgium
  • Bammens, Bert, University Hospitals Leuven, Leuven, Belgium
  • Grundmann, Franziska, University of Cologne, Cologne, Germany
  • Jouret, Francois, University of Liege Hospital (ULg CHU), Liege, Belgium
  • Liebau, Max, University Hospital Of Cologne; Children's Hospital, Koeln, Germany
  • Mueller, Roman-Ulrich, Dept. 2 of Internal Medicine, University of Cologne, Koeln, Germany
  • Perrone, Ronald D., Tufts Medical Center, Boston, Massachusetts, United States
  • Schaefer, Franz S., University of Heidelberg, Heidelberg, BW, Germany
  • Pao, Christina, Otsuka Pharmaceutical Development and Commercialization, Princeton, New Jersey, United States
  • Mekahli, Djalila, KULeuven, Leuven, Belgium

In ADPKD, there is currently limited information whether early diagnosis and management improve outcomes. We studied the implications of early diagnosis on outcome.


A post hoc analysis of TEMPO 3:4, a prospective, double-blind RCT in adults with ADPKD, with eCr ≥60 mL/min and TKV ≥750 mL. Comparison between patients diagnosed at age ≤18 years (childhood diagnosis [CD]) and >18 years (adult diagnosis [AD]).


Patients were classified as CD in 20%, AD in 76% (Table 1), and unknown age at diagnosis in 4% (not shown) of the cases. At time of TEMPO 3:4 inclusion, CD were younger and had better eGFR than AD (Table 1). There were no significant differences in TKV, hypertension or RAASi use. Rates of TKV growth and eGFR changes by age at diagnosis are shown in Table 2.


The characterization of CD patients in TEMPO 3:4 shows that these participants were more severely affected based on a larger age-adapted TKV. Despite this fact, yearly TKV increase and loss of eGFR in the placebo arm of the study showed a tendency (NS) to be milder in the CD cohort. These data suggest the need for further evaluation of early intervention in the treatment of ADPKD.


  • Commercial Support